FDA WARNING_LETTER - benjaminmcevoy.com - May 12, 2020

On May 14, 2020, the FDA and FTC issued a Warning Letter to Benjamin McEvoy regarding unapproved and misbranded products related to COVID-19. The agencies reviewed www.benjaminmcevoy.com on May 6 and May 12, 2020, observing that the website participates in the Amazon Associates program, promoting dietary supplements with claims implying they can mitigate, prevent, treat, diagnose, or cure COVID-19.

These claims cause the Amazon associate products to be unapproved new drugs under section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) and misbranded drugs under section 502 (21 U.S.C. § 352). Introducing or delivering these products into interstate commerce is prohibited under sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)), and misbranding after shipment in interstate commerce is prohibited under section 301(k) (21 U.S.C. § 331(k)).

The letter cites examples of claims from https://benjaminmcevoy.com/top-7-supplements-boosting-immune-system/ that establish intended use for COVID-19. The FDA requests immediate cessation of promoting and participating